JPMorgan Upgrades Biogen to Overweight, Raises Price Target to $300

JPMorgan upgraded Biogen to Overweight from Neutral and raised its price target to $300 from $210, citing a more compelling pipeline catalyst outlook and improved long-term growth prospects.